<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345590</url>
  </required_header>
  <id_info>
    <org_study_id>01/15</org_study_id>
    <nct_id>NCT02345590</nct_id>
  </id_info>
  <brief_title>Eplerenone in the Management of Abdominal Aortic Aneurysms</brief_title>
  <official_title>Eplerenone in the Management of Abdominal Aortic Aneurysms: A Proof-Of-Concept Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Weakening and expansion of the main abdominal artery (abdominal aortic aneurysm, AAA) is a
      common problem in older Australians. The majority of AAAs are small (&lt;55 mm) and affect
      90,000 individuals in Australia and 4.5 million world-wide. Currently, the only treatment
      available for AAA is surgery. However, surgical therapies are not effective for small AAAs,
      and these patients undergo a program of repeat imaging and consultation to monitor the size
      of the aneurysm and symptoms.

      This proposal is aimed at addressing the urgent need to identify a medical treatment able to
      limit progression of AAAs.

      The study design and rationale are based on strong preclinical evidence supporting the value
      of eplerenone (an agent indicated for treatment of heart failure) in limiting AAA
      progression. If proved effective, this medication would:

        1. Reduce the number of patients requiring costly surgery

        2. Reduce the number of surgery related deaths and complications

        3. Provide a therapy suitable for the rapidly expanding elderly age group who have AAAs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>abdominal aortic aneurysm maximum orthogonal diameter</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Aortic Aneurysm, Abdominal</condition>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg Eplerenone once daily for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo once daily for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>25mg of eplerenone</description>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_label>Matching placebo</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals aged over 60years (inclusive); AAA measuring a maximum diameter of 30-49
             mm on MRI; no current indication for AAA repair according to the treating physician or
             expectation that this will be revised within the next year; high likelihood of
             compliance with treatment over 12 months; stable medication regime for the last six
             months; have given signed informed consent to participate in the study.

        Exclusion Criteria:

          -  Serum potassium concentration of more than 5.0 mmol/L before randomisation; evidence
             of renal impairment defined as serum creatinine&gt;133 umol/L or creatinine clearance of
             &lt;60 mL/min; known significant renal stenosis (&gt;70%) of one or both renal arteries;
             evidence of liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function
             defined as aspartate aminotransferase, alanine aminotransferase or total bilirubin
             &gt;1.5x the upper limit of normal; evidence of primary aldosteronism (plasma
             aldosterone/renin ratio&gt;650 pmol/L); electrolyte imbalance; active gout; use of MR
             antagonists; use of potassium-sparing diuretics, or potassium supplements; individuals
             with claustrophobia or a history of any metallic prosthetic implant contraindicating
             MRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leah Isles, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leah Isles, MBBS</last_name>
    <phone>61 3 90763263</phone>
    <email>l.iles@alfred.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Taylor, MBBS</last_name>
    <phone>61 3 90763263</phone>
    <email>a.taylor@alfred.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baker IDI</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Isles, MBBS</last_name>
      <phone>61 3 90763263</phone>
      <email>l.iles@alfred.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Andrew Taylor, MBBS</last_name>
      <phone>61 3 90763263</phone>
      <email>a.taylor@alfred.org.au</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Heart Centre, Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Isles, MBBS</last_name>
      <phone>61 3 90763263</phone>
      <email>l.iles@alfred.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Andrew Taylor, MBBS</last_name>
      <phone>61 3 90763263</phone>
      <email>a.taylor@alfred.org.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

